G1 Therapeutics

GTHX62

$7.150.00%$0.00

GTHX62

$7.15

0.00%$0.00

Performance History

Key Stats
Open	$7.15
Prev. Close	$7.15
EPS	-0.86
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	7.15	7.15
52 Week Range	1.08	7.19

Ratios







EPS	-0.86

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About G1 Therapeutics (GTHX)

G1 Therapeutics Inc (GTHX) is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel treatments for cancer. The company is dedicated to improving the lives of patients with cancer by developing therapies that target the underlying mechanisms of the disease. GTHX is committed to leveraging its expertise in cell cycle biology and drug discovery to develop innovative treatments for patients with unmet medical needs.

With a strong pipeline of potential therapies, G1 Therapeutics Inc is poised for growth in the biopharmaceutical industry. The company's lead product candidate, trilaciclib, is being studied in multiple clinical trials for various cancer indications. Trilaciclib has the potential to become a first-in-class therapy that can improve outcomes for cancer patients undergoing chemotherapy. GTHX is also developing other drug candidates, including lerociclib and G1T48, to target specific types of cancer.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. John E. Bailey Jr.
Headquarters: Research Triangle Park
Employees: 170
Exchange: NASDAQ

Keep an eye on G1 Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is G1 Therapeutics 's (GTHX) price per share?

The current price per share for G1 Therapeutics (GTHX) is $7.15. The stock has seen a price change of $0 recently, indicating a 0% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for G1 Therapeutics (GTHX)?

For G1 Therapeutics (GTHX), the 52-week high is $7.19, which is 0.56% from the current price. The 52-week low is $1.08, the current price is 562.04% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is G1 Therapeutics (GTHX) a growth stock?

G1 Therapeutics (GTHX) has shown an average price growth of -3.66% over the past three years. It has received a score of 90 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying G1 Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is G1 Therapeutics (GTHX) stock price performance year to date (YTD)?

As of the latest data, G1 Therapeutics (GTHX) has a year-to-date price change of 129.9%. Over the last three months, the change has been 0.42%. Over the past six months, the figure is 69.43%. Looking at a longer horizon, the five-year price change stands at -69.41%.

help

Is G1 Therapeutics (GTHX) a profitable company?

G1 Therapeutics (GTHX) has a net income of -$47.97M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 91.28% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -21.37% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $82.51M, with a revenue growth rate of 60.84%, providing insight into the company's sales performance and growth. The gross profit is $75.32M. Operating income is noted at -$39.53M. Furthermore, the EBITDA is -$37.39M.

help

What is the market capitalization of G1 Therapeutics (GTHX)?

G1 Therapeutics (GTHX) has a market capitalization of $377.22M. The average daily trading volume is 1.71M, indicating the stock's liquidity and investor engagement.

News

Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer

MERGERS AND ACQUISITIONS

SHAREHOLDER INVESTIGATIONS

Aug 15, 2024

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP)

PRODUCT / SERVICES ANNOUNCEMENT

EXCHANGE ANNOUNCEMENT

Jul 1, 2024

G1 Therapeutics Added to the Russell 2000® and 3000® Indexes

Jun 30, 2024

Wall Street Breakfast: The Week Ahead

Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday

CALENDAR OF EVENTS

HEALTH

PRODUCT / SERVICES ANNOUNCEMENT

Jun 24, 2024

G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)

Performance History

Score Breakdown

Welcome to Stocklytics

Analyst Forecast

Analyst Ratings

About G1 Therapeutics (GTHX)

Keep an eye on G1 Therapeutics

Frequently Asked Questions

What is G1 Therapeutics 's (GTHX) price per share?

What is the 52-week high and low for G1 Therapeutics (GTHX)?

Is G1 Therapeutics (GTHX) a growth stock?

What is G1 Therapeutics (GTHX) stock price performance year to date (YTD)?

Is G1 Therapeutics (GTHX) a profitable company?

What is the market capitalization of G1 Therapeutics (GTHX)?

News

Take Your Investments to a Whole New Level